Jump to
Abstract
Objective—The activation of valve interstitial cells (VICs) toward an osteogenic phenotype characterizes aortic valve sclerosis, the early asymptomatic phase of calcific aortic valve disease. Osteopontin is a phosphorylated acidic glycoprotein that accumulates within the aortic leaflets and labels VIC activation even in noncalcified asymptomatic patients. Despite this, osteopontin protects VICs against in vitro calcification. Here, we hypothesize that the specific interaction of osteopontin with CD44v6, and the related intracellular pathway, prevents calcium deposition in human-derived VICs from patients with aortic valve sclerosis.
Approach and Results—On informed consent, 23 patients and 4 controls were enrolled through the cardiac surgery and heart transplant programs. Human aortic valves and VICs were tested for osteogenic transdifferentiation, ex vivo and in vitro. Osteopontin–CD44 interaction was analyzed using proximity ligation assay and the signaling pathways investigated. A murine model based on angiotensin II infusion was used to mimic early pathological remodeling of the aortic valves. We report osteopontin–CD44 functional interaction as a hallmark of early stages of calcific aortic valve disease. We demonstrated that osteopontin–CD44 interaction mediates calcium deposition via phospho-Akt in VICs from patients with noncalcified aortic valve sclerosis. Finally, microdissection analysis of murine valves shows increased cusp thickness in angiotensin II-treated mice versus saline infused along with colocalization of osteopontin and CD44 as seen in human lesions.
Conclusions—Here, we unveil a specific protein–protein association and intracellular signaling mechanisms of osteopontin. Understanding the molecular mechanisms of early VIC activation and calcium deposition in asymptomatic stage of calcific aortic valve disease could open new prospective for diagnosis and therapeutic intervention.
Introduction
Calcific aortic valve disease (CAVD) is a slowly progressive multifactorial disorder more common with age, without being an inevitable consequence of aging.1–5 Initial phases of the disease include mild thickening of the valve, whereas more advanced stages are associated with impaired leaflet motion and resistance to blood flow.6–9 These conditions are known as aortic valve sclerosis (AVSc) and calcific aortic valve stenosis, respectively. Aortic sclerosis is a hallmark of several cardiovascular conditions ranging from chronic heart failure and myocardial infarction to calcific aortic stenosis.1,2,4,5,8 AVSc is present in 25% to 30% of patients over 65 years of age, and it is characterized by thickening of the leaflets with none or marginal effects on the mechanical proprieties of the valve making its presentation asymptomatic.1,2,4,5,10,11 In addition, aortic sclerosis is challenging to define due to the variable and qualitative nature of its description by echocardiographic evaluation.1,2,4,5,8 Moreover, tissues from asymptomatic patients with aortic sclerosis are generally unavailable to investigators because these valves are not surgically replaced until moderate to severe stenosis occurs. Noteworthy, once aortic sclerosis is detected, there is an increased risk of cardiovascular events.12 At the onset of early symptoms of calcific aortic stenosis, the survival curve declines rapidly from the expected event-free curve, with a dramatic deviation in case of severe symptomatic stenosis.4,11,13 Despite its high prevalence, little is known about the initiating pathogenetic mechanisms determining the activation of valve interstitial cells (VICs) toward osteogenic-like phenotype and calcification.
Our extensive work on the pathogenesis of the early stage of CAVD has demonstrated that noncalcified leaflets from patients with AVSc can be induced to express markers of osteogenic transdifferentiation (osteopontin, osteonectin, runt-related transcription factor 2, α-smooth muscle actin, and alkaline phosphatase).6,7,14,15 Notably, we can promote biomineralization of noncalcified tissues through the combinatory effect of bone morphogenetic protein 4 (BMP4) and mechanical stimulation (15% stretch at 1 Hz)11 or through oxidative stress.14 VIC activation is a hallmark of pathological remodeling of the aortic valve leaflet even in the absence of clinical symptoms.6,14,16–21 Oxidative damage, altered mechanical stress, several cytokines, and growth factors have been recently reported as markers of VIC activation, resulting in the expression of osteogenic markers.6,14,17,18,20–24 Additionally, we reported that human VICs can be induced to transdifferentiate with a repopulated tissue-engineered aortic valve model, based on porcine extracellular matrix scaffold with results showing overexpression of osteopontin and other osteogenic markers.6 Furthermore, we demonstrated an active role of phosphorylated osteopontin as an important inhibitor of in vitro vascular calcification.17,25,26 We previously reported that circulating osteopontin levels are elevated in patients with CAVD when compared with healthy controls.17,26–28 Because the biological function of osteopontin in vitro is to inhibit calcium deposition, it has been proposed that the increasing level of osteopontin in diseased tissue reflects a compensatory mechanism aimed to block biomineralization. Here, we investigate how osteopontin prevents in vitro calcification via a protein–protein interaction with one of its receptors.
The primary receptors for osteopontin are those integrins that present the central integrin binding motif RGD.26 In addition to the integrin, the C-terminal fragment of osteopontin binds directly to CD44v6 in an RGD-independent manner,29 inducing cell migration and regulating calcium deposition.26,30,31 This receptor consists of 20 exons, where the first five and the last five are constant and the others are present in the isoforms. Exons 1 to 16 encode the extracellular domain, exon 17 encodes the transmembrane domain, and exons 18 and 19 encode the cytoplasmic domain. The 10 exons located between 5a and 14 are subjected to alternative splicing, resulting in the generation of CD44 variants. CD44 is a multifunctional receptor, which plays a role in cell adhesion, cell trafficking, presentation of chemokine and growth factors, and transmission of growth signals and signals mediating hematopoiesis and apoptosis.31
Using human-derived tissues, obtained through the heart transplant program and the cardiovascular surgery department at the University of Pennsylvania, we aimed to investigate, ex vivo and in vitro, the role of osteopontin–CD44 interaction governing calcium deposition in valve interstitial cells from patients with noncalcified AVSc. Furthermore, we implemented a murine model based on chronic infusion of angiotensin II (Ang II)32–35 to mimic early aortic valve tissue remodeling and expression of osteogenic markers.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Osteopontin–CD44 Functional Interaction as a Hallmark of Early Stages of CAVD
On informed consent, 27 patients were selected from our cardiac bioregistry. Four controls and 18 aortic valve sclerotic tissues were obtained through the heart transplant research program. Five aortic valve stenotic tissues were collected during aortic valve replacement procedures from patients with end-stage CAVD (Table). Aortic valve calcification was assessed, and a calcium score of 1 to 4 was assigned for each patient by a single cardiologist based on the method described by Rosenhek et al36: 1, no calcification; 2, mildly calcified (small isolated spots); 3, moderately calcified (multiple larger spots); and 4, severely calcified (extensive thickening and calcification of all cusps; Table).
Patient Demographics
In control aortic valves, both CD44 and osteopontin expression are barely detectable throughout the entire leaflets (Figure 1A and 1B). By contrast, in sclerotic and stenotic aortic valves, the expression of both proteins is higher when compared with healthy controls. Moreover, the stenotic tissues have a uniform expression, whereas the sclerotic ones have a major concentration of CD44 and osteopontin in the ventricularis region (Figure 1A and 1B). According to echocardiographic analysis, controls and AVSc do not show calcium within the leaflets, whereas aortic valve stenosis shows side-specific calcium accumulation (Figure I in the online-only Data Supplement). To test ex vivo functional interaction, between osteopontin and CD44, proximity ligation assay was performed as described in the Material and Methods section. Reaction products (red dots), representing the direct binding between osteopontin and CD44, show the extracellular functional interaction of these 2 proteins in both sclerotic and stenotic tissues (≈10-fold increment) when compared with control aortic valves (Figure 1C and 1D).
CD44–osteopontin (OPN) functional interaction as a hallmark of early stages of calcific aortic valve disease (A and B). Representative images showing histological analysis of human aortic valve (AV; controls, sclerosis, and stenosis). Immunohistochemistry staining for CD44 and OPN. Bar represents 0.5 mm. C, Proximity ligation assay (PLA), red fluorescent dots indicate reaction product showing extracellular binding between CD44 and OPN. Magnification ×100. D, Bar graph representing PLA quantification in controls, sclerotic, and stenotic aortic valves. *P<0.05. E, Configuration of testing sample in tension bioreactor. F, Bar graph representing PLA quantification in sclerotic aortic valves under static or dynamic (15% stretch at 1 Hz) conditions in the absence or presence of bone morphogenetic protein 4 (BMP4; 100 ng/mL). *P<0.05. G, PLA showing CD44/OPN binding in AV sclerotic tissue at 6 days under static or dynamic (15% stretch at 1 Hz) conditions in the absence or presence of bone morphogenetic protein 4 (BMP4; 100 ng/mL).
We previously showed that BMP4 and mechanical stimulation induce both osteogenic markers expression and biomineralization of human noncalcified aortic valve sclerotic tissues,6 and we tested whether osteopontin–CD44 binding was also regulated by biomechanical stimulation. We therefore applied 15% stretch at 1 Hz in the presence or absence of BMP4 (100 ng/mL), using a tensile bioreactor to mimic the stress on the valve during the cardiac cycle (Figure 1E).6 As an internal control, native tissues were treated statically in the presence or absence of BMP4 (100 ng/mL). Cyclic stretch of the leaflets does not damage leaflet morphology and maintains native extracellular matrix structure and cellular composition.37,38 As shown in Figure 1F and 1G, the osteopontin–CD44 binding was influenced only by BMP4, independently of the mechanical stimuli.
Osteopontin and CD44 Protect Human Sclerotic Valve Interstitial Cells From Calcification Induced by BMP4
To test the role of osteopontin–CD44, in the regulation of VIC osteogenic transdifferentiation and calcification under BMP4, we isolated primary interstitial cells from 10 patients (2 controls, 4 sclerotic, and 4 stenotic) according to the methods described by Branchetti et al.14 Phenotypic stability was assessed after isolation, and VICs were used between passage 2 and 4. Figure 2A and 2B shows a schematic representation of structure, epitopes, domains, and exons of CD44 standard isoform (CD44s) and its possible variants (CD44v). It has been shown that osteopontin binds the variant 6 of CD44 (CD44v6).29 We therefore tested whether CD44v6 was present in aortic valve–derived VICs of our 3 cohorts of patients. As shown in Figure 2C and 2D, all the tested human isolated VICs from controls, sclerotic, or stenotic patients express CD44v6 isoform, independently of the progression of the disease.
CD44–osteopontin (OPN) interaction on isolated valve interstitial cells (VICs) from asymptomatic patients with aortic valve sclerosis (AVSc). A, Schematic structure of CD44s and CD44v that has an additional longer stem, which contains the variant exon(s). B, CD44 gene consists of 20 exons, exons 1 to 5 (N-terminal domain) and exons 15 to 19 (C-terminal domain). Exons 5a to 14 (v1–v10) generate CD44 variants through alternative splicing. C, Polymerase chain reaction (PCR) product obtained using primers CD44v6 fw and CD44v6 rv on human isolated VICs, 2 controls, 4 patients with sclerosis, and 4 patients with stenosis. D, Bar graph quantification of PCR products for controls, AVSc, and patients with aortic valve stenosis. E, Proximity ligation assay (PLA) showing CD44/OPN binding in aortic valve sclerotic VICs at 0 hours, 4 hours, 24 hours, and 6 days after in vitro treatments (100 ng/mL) in the presence or absence of neutralizing antibody (NAb) CD44 (5 μg/mL). Magnification ×100. F, Line graph represents PLA quantification. *P<0.05. BMP4 indicates bone morphogenetic protein 4.
In a time-course experiment, we show that in AVSc-derived VICs, the binding between osteopontin and CD44 is highly increased in response to BMP4 treatment (Figure 2E and 2F). The proximity ligation assay products (red dots), representing the interaction between the extracellular portion of the transmembrane receptor CD44 and osteopontin, increases after 4 hours of BMP4 treatment and persists ≤6 days. A neutralizing antibody against CD44 (NAb-CD44), recognizing the epitope 2 (conserved region in the extracellular domain, Figure 2A), competes with osteopontin binding site to CD44 and can prevent the osteopontin–CD44 interaction induced by BMP4 (Figure 2E and 2F).
We then treated isolated sclerotic VICs for 12 days in the presence or absence of BMP4 (100 ng/mL) following protocols previously described.6 Using quantitative real-time polymerase chain reaction, we analyzed the expression of osteopontin (3.3-fold increase) and alkaline phosphatase (2.2-fold increase) under BMP4 treatment to demonstrate its role in controlling the VICs activation toward an osteogenic-like phenotype (P<0.05; Figure 3A). In a time-course experiment, AVSc-derived VICs were treated for 3, 6, and 12 days with BMP4 (100 ng/mL) and analyzed for CD44(v6) and osteopontin expression. As shown in Figure 3B to 3F, and according to our previous results,6 BMP4 treatment increases osteopontin expression in a time-dependent fashion either by real-time polymerase chain reaction (Figure 3A and 3B) or Western blotting (Figure 3C and 3D) while CD44 protein expression (Figure 3C and 3D) and CD44v6 mRNA (Figure 3E and 3F) were not significantly affected by BMP4 treatment and remain constant through the 12 days (Western blotting and real time).
CD44 and osteopontin (OPN) protect human sclerotic valve interstitial cells (VICs) from calcification induced by bone morphogenetic protein 4 (BMP4). A, Bar graph representing fold change in gene expression of OPN and alkaline phosphatase (ALP) in aortic valve sclerotic VICs after 12 days of in vitro treatment of BMP4 (100 ng/mL). B, Osteopontin quantification by real-time polymerase chain reaction (RT-PCR) of AVSc-derived VICs under BMP4 treatments at 0, 3, 6, and 12 days. C, Western blotting of protein extracts from AVSc-derived VICs treated with BMP4 (100ng/mL) for 3, 6, and 12 days. Antibodies against CD44, OPN, and GAPDH were used. D, Quantification of Western blotting. E, RT-PCR for CD44v6 and GAPDH of total RNA extracted from AVSc-derived VICs treated with BMP4 (100 ng/mL). F, RT quantification. G, Bar graph represents calcium deposition on aortic valve sclerotic VICs after 12 days of treatment with BMP4 (100 ng/mL), neutralizing antibody (NAb) OPN (5 μg/mL), NI-IgG (5 μg/mL), and their combinations. *P=0.05. H, Alizarin red staining representing calcium deposition (red) on VICs after 12 days treatment with BMP4 (100 ng/mL), NAb CD44 (5 μg/mL), NAb OPN (5 μg/mL), and their combination.
It has been widely demonstrated that osteopontin is able to prevent calcium deposition in vitro.26,39 In this study, we tested whether, under BMP4 stimulation, osteopontin is able to prevent calcium deposition by binding to CD44 in VICs isolated from patients with AVSc. AVSc-derived VICs were treated with BMP4 (100 ng/mL) for 12 days: despite the increased level of alkaline phosphatase (Figure 3A). AVSc-derived VICs do not show calcium accumulation (Figure 3G and 3H). However, blocking osteopontin–CD44 interaction (by neutralizing antibody against either CD44 or osteopontin) induced calcium deposition, +3.4 and +1.9 (P<0.05) fold increase, respectively, when compared with BMP4 treatment alone (Figure 3G and 3H). These results suggest that the functional interaction between osteopontin and CD44 protects AVSc-VICs from calcium deposition.
Akt Phosphorylation Induced by Osteopontin–CD44 Is Required to Protect Human Sclerotic Valve Interstitial Cells From Calcium Deposition
We then investigated the intracellular signaling pathway activated by BMP4 and osteopontin–CD44 in human-derived VICs. Extensive work has reported a direct activation of MAPK (mitogen-activated protein kinase) signaling pathway by osteopontin in different cell lines.30,40,41 We previously demonstrated that osteopontin mediates calcium deposition independently of p38 and ERK1/2 activation.26 Here, we tested Akt phosphorylation induced by BMP4 through osteopontin. Phosphorylation of SMAD1/5/8 was also tested as an independent signaling pathway activated by BMP4. In our experiment, phospho-Akt is seen by Western blot after 15 minutes, 4 hours, and 24 hours of BMP4 and osteopontin treatments; however, Akt phosphorylation is prevented by pretreatment with a neutralizing antibody against CD44 (NAb–CD44). Furthermore, the phosphorylation of SMAD1/5/8 is BMP4 dependent, and the presence of NAb–CD44 does not affect the SMAD phosphorylation (Figure 4A).
Akt phosphorylation induced by CD44/osteopontin (OPN) is required to protect human sclerotic valve interstitial cells (VICs) from calcium deposition. A, Western blotting of pAkt, Akt 1/2, pSMAD 1/5/8, and GAPDH at 0 hours, 15 minutes, 4 hours, and 24 hours after bone morphogenetic protein 4 (BMP4; 100 ng/mL) in combination with neutralizing antibody (NAb) CD44 (5 μg/mL) or NAb OPN (5 μg/mL). B, Bar graph represents calcium deposition on aortic valve sclerotic VICs after 12 days treatment with BMP4 (100 ng/mL) in the absence or presence of Wortmannin (0.2 mmol/L). *P=0.05. C, Alizarin red staining representing calcium deposition (red) on VICs after 12 days treatment with BMP4 (100 ng/mL) in the presence or absence of Wortmannin (0.2 mmol/L).
We finally evaluated the role of phospho-Akt, induced by osteopontin–CD44 binding, on regulating calcium deposition of VICs derived from patients with noncalcified AVSc. We therefore treated human isolated sclerotic VICs with BMP4 (100 ng/mL) in the presence or absence of Wortmannin (200 nmol/L), a known phosphoinositide-3-kinase/Akt cascade inhibitor. As presented in Figure 4B and 4C, the combination of BMP4 and Wortmannin resulted in an increment of calcium deposits measured by colorimetric assay and Alizarin red staining. These results suggest that Akt phosphorylation induced by osteopontin–CD44 is required to protect human sclerotic valve interstitial cells from calcium deposition.
Ang II Infusion Provokes Remodeling of the Aortic Valve Tissue in Mice
We recently reported that reactive oxygen species (ROS) accumulation is leading VICs activation ex vivo and in vitro,14 with results showing that adenoviral delivery of antioxidant enzymes ameliorates VICs activation and calcification. We therefore used a previously developed32,33 murine model based on chronic Ang II infusion to reproduce ROS accumulation in the cardiac tissue. This model was first developed to induce ascending aortic aneurysm.32–35 The choice of this model has been justified by the role of Ang II in activating constitutive nitric oxide synthase with production of ROS (H2O2 and ONOO) via angiotensin II type I receptors (AT1R) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Using this model, we tested whether ROS accumulation was inducing valve remodeling and how it controlled osteopontin–CD44 expression in vivo. Male wild-type mice (C57BL/6J) were fed with enriched diet and infused with saline (n=12) or Ang II (1000 ng/kg per minute; n=28) for 28 days. Echocardiographic and immunohistological analysis were performed on each animal to test for ROS and osteogenic marker accumulation, osteopontin–CD44 expression, and extracellular matrix remodeling (Table I in the online-only Data Supplement).
Microdissection analysis of murine valve tissue shows increased (P<0.01) cusp thickness in Ang II-treated mice versus saline infused (Figure 5A) without calcium accumulation (Figure 5B), resembling human early aortic valve remodeling.6,14,17 Histological and protein quantification analysis also revealed increased ROS (nitrotyrosine staining) in mice cusps (Figure 5C) as seen in human lesions.14 We then tested the expression of osteopontin, CD44, and other osteogenic markers in our murine model, with results showing that Ang II infusion promotes overexpression of osteopontin and smooth muscle actin (Figure 5D), while—according to previous data—similar expression levels of CD44 were detected (Figure 5E). Finally, we performed coimmunofluorescence experiments to test the colocalization of osteopontin and CD44 on murine aortic valve tissues. As shown in Figure 5F, our confocal microscope analysis shows colocalization of osteopontin–CD44 in tissue exposed to Ang II.
Angiotensin II (Ang II) infusion provokes remodeling of the aortic valve tissue in mice. A, Hematoxylin–eosin staining of cross section of mice hearts harvested 28 days after saline or Ang II infusion (magnification, ×10 and ×43). Bar graph representing leaflet thickness (μm). B, Alizarin red staining showing minimal calcium accumulation in the aortic valve of Ang II-treated mice. C, Nitrotyrosine staining showing oxidative damage accumulation in the aortic valve of Ang II-treated mice (magnification, ×10 and ×60). D and E, Osteopontin (OPN), smooth muscle actin (SMA), and CD44 expression detected by immunofluorescence in aortic valve leaflets. Images were taken using confocal microscopy (magnification, ×100). F, Coimmunofluorescence showing OPN (red) and CD44 (green) colocalization in aortic valve leaflets (magnification, ×60). DAPI indicates 4’,6-diamidino-2-phenylindole; and ROS, reactive oxygen species.
Discussion
Over the last decade, several clinical trials, mostly extensions of atherosclerosis-related studies (collectively referred as statin trials), have been performed to halt the progression of CAVD with contradictory results. The early enthusiastic findings documenting a reduction in the progression of CAVD have been questioned by later randomized studies, which show substantial equivalence between treatments and placebo.42–46 It has been proposed that CAVD therapy in these trials may have been initiated too late in the course of the disease to be effective.47–50 Once sclerosis is detectable, there is an increased risk of cardiovascular events. In addition, human aortic sclerotic tissues are generally not available to investigators because these valves are not surgically replaced until moderate to severe aortic stenosis occurs.1,11,23,51,52 At the onset of even mild symptoms, survival rate decreases from the event-free population, with a dramatic decline in case of severe symptomatic aortic valve stenosis.11,13 We now understand that aortic valve stenosis is just the end stage of a disease that progresses from the microscopic early changes of aortic sclerosis to, in a subset of patients, asymptomatic and then symptomatic severe calcific stenosis. In vitro and in vivo studies have shown that valve calcification is an active process controlled by inflammatory mediators and regulators of osteogenic-like differentiation of VIC in the fibrosa layer of leaflets. We have extensively investigated the early asymptomatic stage of CAVD using a human bioregistry of tissue and VIC-derived cells.6,7,14,15,26,28 Because of its asymptomatic presentation, little is known about the molecular mechanisms underlying tissue remodeling and VIC activation in patients with AVSc. Here, we unveil the specific functional association of osteopontin with CD44v6 and the intracellular signaling mechanisms controlling calcium deposition on VIC derived from noncalcified aortic valve tissues.
High levels of osteopontin in native human calcified aortic valves from patients undergoing aortic valve replacements have been shown by immunohistochemistry, reverse transcription–polymerase chain reaction, Western blotting, and in situ hybridization analyses.7,30,40 In addition to native valves, increased osteopontin levels were also found by immunohistochemistry in calcified valve allografts and in areas of calcification in glutaraldehyde-pretreated bioprosthetic porcine valves.53,54 Elevated circulating osteopontin levels are also reported in other cardiovascular diseases, such as atherosclerosis, ischemic heart disease, heart failure, and rheumatic mitral stenosis.30 Osteopontin is of special interest for CAVD because it is the only described biomarker directly involved in the ectopic and dystrophic calcification phenomenon that occurs during native and bioprosthetic valve degeneration. Interestingly, circulating levels of osteopontin are also elevated in patients with signs of AVSc, suggesting that osteopontin could also be used as biomarker to label patients at risk to develop severe stenosis.17,28 We have reported the role of osteopontin on VICs, vascular smooth muscle cells, and endothelial cells.26 Our analysis showed that osteopontin activates the same intracellular signaling pathways in cultured endothelial and smooth muscle cells and in excised aortic valve tissues. In addition, our data support the concept that the biological function of osteopontin is mediated by CD44.26
This study provides several new insights into the specific interaction of osteopontin with CD44 and the intracellular signaling controlling calcium deposition in human sclerotic-derived VICs. As discussed, tissue from early stages of AVSc is extremely difficult to obtain because these valves are mechanically functional and are not indicated for repair or replacement. However, our collaborations with the Gift of Life program and with the heart transplant program allow us to rely on this unique collection of human specimens. Using this major resource, we demonstrated a specific osteopontin–CD44 functional interaction in early asymptomatic stage of CAVD. We then show, in vitro, that preventing osteopontin–CD44 interaction results in calcium accumulation of VIC obtained from noncalcified patients with AVSc after treatments with BMP4. Finally, using neutralizing antibodies and general inhibitors of intracellular signaling pathways, we unveil that Akt phosphorylation induced by osteopontin–CD44 is required to protect human sclerotic valve interstitial cells from calcium deposition. Our data provide novel insights into the intracellular mechanisms controlling osteopontin, and in general VIC activation and calcification, in human AVSc-derived cells. Specifically, in healthy valve pro-osteogenic markers such as BMP4 and osteopontin are barely detectable. We, and others, have shown that with the development of early stages, there is an accumulation of oxidative damage, TGF-β-related cytokines, and changes in the biomechanical proprieties of the aortic valve leaflets, resulting in increased levels of pro-osteogenic factors, such as BMP4.6,14,17,21,23,24 These pro-osteogenic conditions trigger the expression of osteopontin that has been widely reported to protect against calcium accumulation in vitro.17,26,40,55–57 Here, we demonstrate that one of the mechanisms by which osteopontin is preventing BMP4-mediated biomineralization is through the functional interaction with CD44v6. We show that the disruption of CD44–osteopontin functional interaction (blocking osteopontin, CD44, or their downstream signaling pathway [pAkt]) results in calcium deposition in vitro.
To conclude, it is important to discuss the central role of osteopontin and other matricellular proteins in controlling valve homeostasis. Matricellular proteins are a class of nonstructural and secreted proteins that exert regulatory functions through direct binding to cell surface receptors, other matrix proteins, and soluble extracellular factors.58 Over the past few years, several novel matricellular proteins have been indentified: SIBLING (osteopontin,17,30,58 DMP1,58,59 and BSP58,60,61), CCN (Cyr61,58,62,63 CTGF,58,62,64 and Nov58,65), and other matricellular proteins (osteonectin,58,66 thrombospondin 1 and 2,67,68 and tenascin69,70) are involved in various physiological and pathological conditions.61,71,72 Matricellular proteins perform their regulatory role on extracellular matrix by sequestering growth factors, binding ions like Ca2+, and inhibiting proteases by direct binding. Matricellular proteins are also involved in promoting cellular differentiation by activating cytokines, binding cell-surface receptors, and mediating the biomechanical transduction. However, despite their dual role of mediators of cell and matrix homeostasis, the functional role of these molecules on the cellular components and extracellular matrix microstructure of the aortic valve progression of CAVD has not been fully elucidated.
Osteopontin is involved in several processes central for maintaining and controlling both endothelial and interstitial cell function.26,30,40 Osteopontin–αvβ3 interaction is important for osteoclast migration and resorption as well as smooth muscle cell migration and adhesion. In addition, osteopontin acts as a cytokine playing important roles in the migration and invasion of several tumor cells.61,73 In addition, osteopontin is regarded to be an important angiogenic factor in several pathologies.30,40 The pleiotropic function of osteopontin is tightly regulated at different levels, including protein–protein association and transcriptional and post-translational levels. It is possible that different osteopontin post-translational modifications enable the protein to bind different receptors with variable affinity and therefore regulate a differential biological response within the aortic valve leaflets.7,26,74,75 It would therefore be important to investigate how these osteopontin variants affect the functional binding with CD44.
In a recent work, we have also reported a direct effect of oxidative stress on the expression of osteopontin and other markers of VICs activation,14 with adenoviral delivery of antioxidant enzymes ameliorating this effect. We could therefore hypothesize that the molecular mechanisms presented in this study represent a general mechanism of regulation of VIC activation. Therefore, we developed a murine model of VIC activation based on Ang II accumulation. The choice of this model has been justified by the role of Ang II in activating constitutive nitric oxide synthase with production of ROS (H2O2 and ONOO) via AT1R and NADPH oxidase. Using this model, we tested whether ROS accumulation was inducing valve remodeling and how it controlled osteopontin–CD44 expression in vivo. Our data show that ROS accumulation in murine aortic valve tissue is associated with cusp remodeling, resembling human early lesion and expression of osteogenic markers, such as osteopontin, and its receptor CD44, smooth muscle actin, and SOX9. These data are in accordance with the expression of these molecules in the human lesions.14 Several limitations are associated with this model: first, Ang II is not specific for aortic valve remodeling, but it induces remodeling of different cardiac and vascular tissues; second, the functional interaction of osteopontin with CD44v6 was not successfully detected under the tested experimental conditions in the murine model. This model is, however, potentially important because it could be used to test in vivo specific peptides or small molecules targeting directly osteopontin, CD44, or both. Understanding the functional role of osteopontin and other matricellular proteins in controlling VIC activation and calcium deposition in early asymptomatic stage of CAVD could open new prospective for diagnosis and therapeutic intervention.
Sources of Funding
This project was supported by the Harrison Memorial Fund of the University of Pennsylvania Perelman School of Medicine (G. Ferrari). This work was also partially supported by a collaborative research grant sponsored by the Valley Hospital Foundation–Marjorie G. Bunnell Charitable Fund (G. Ferrari and J.B. Grau).
Disclosures
None.
Footnotes
The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.113.303017/-/DC1.
-
- Nonstandard Abbreviations and Acronyms
- Ang II
- angiotensin II
- AVSc
- aortic valve sclerosis
- BMP4
- bone morphogenetic protein 4
- CAVD
- calcific aortic valve disease
- ROS
- reactive oxygen species
- VICs
- valve interstitial cells
- Received December 4, 2013.
- Accepted July 15, 2014.
- © 2014 American Heart Association, Inc.
References
Significance
This article is aimed to investigate the functional interaction of osteopontin and CD44 in human-derived interstitial cell from patients with aortic valve sclerosis, the early asymptomatic phase of calcific aortic valve disease. Calcific aortic valve disease, the main cause of aortic valve replacement in the United States, is a multifactorial process more common with age, although not an inevitable consequence of aging. Because of the shift in demographic by the aging population, surgical replacement of the aortic valve is projected to reach >850 000 cases worldwide by 2050, compared with 300 000 aortic valve replacements that take place currently. Although final stages of the disease (aortic valve stenosis) are well described, the cellular mechanisms associated with initiating phases remain largely unknown due to the asymptomatic presentation of aortic valve sclerosis. In this study, conducted entirely using human-derived interstitial cells from patients with noncalcified aortic valve sclerosis, we demonstrated that osteopontin–CD44 interaction protects the interstitial cells from calcium deposition via Akt phosphorylation.
This Issue
Jump to
Article Tools
Share this Article
- Osteopontin–CD44v6 Interaction Mediates Calcium Deposition via Phospho-Akt in Valve Interstitial Cells From Patients With Noncalcified Aortic Valve SclerosisSignificance
